On-line Table 1: Methodology of the source studies

	Prospective			Retrospective		
	Study A[11]	Study B[12]	Study C[13]	Study D[14]	Study E[15]	Study F[16–20]
Inclusion criteria	IV rtPA candidates with NIHSS score ≥10, no age limit	NIHSS score 4–23, arterial occlusion on diagnostic angiogram, no age limit	NIHSS score ≥8, non-IV candidate; age, 18–77 yr	Non-IV candidates; NIHSS score ≥16, onset >3 hours or recent major surgery, no age limit	NIHSS score ≥4, arterial occlusion on angiogram, no age limit	NIHSS score ≥4, no age limit
Time window	0–3 hours	3–6 hours	0–6 hours (anterior circulation), <24 hours (posterior circulation)	0–3 hours (if NIHSS score ≥16 or if recent surgery), else >3 hours	0–3 hours (if NIHSS score ≥10) ± IV rtPA, 3–6 hours (anterior circulation, NIHSS score ≥4), 3–24 hours (BA occlusion)	0–6 hours (anterior circulation), <12 hours (posterior circulation)
IA pharmacologic agent	None	Reteplase	rtPA or reteplase	Reteplase	rtPA, urokinase or tenecteplase	rtPA, prourokinase or tenecteplase
IA mechanical procedure	Angioplasty for large vessels, snare for small vessels	No	Sonographic transmission	Angioplasty and/or stenting for large vessels, snare for small vessels	Combination of angioplasty, stent, MERCI device, and snare	Angioplasty and/or stenting for large vessels, snare for small vessels
Gp IIb/IIIa inhibition	No	Abciximab	No	No	Eptifibatide (7 cases)	No

On-line Table 2: Results of the source studies

	Study A[11]	Study B[12]	Study C[13]	Study D[14]	Study E[15]	Study F[16–20]
Sample size	24	20	16	46	41	123
Age (mean ± SD)	65 ± 18	65 ± 18	61 ± 12	70 ± 16	67 ± 17	65 ± 14
Women	13 (54%)	7 (35%)	8 (50%)	19 (41%)	15 (37%)	57 (47%)
Initial NIHSS score[a]	17 (11–21)	15 (6–23)	19.5 (9–40)	20.5 (5–43)	16 (5–42)	16 (4–30)
Time to treatment (hr)	Time to IA (mean ± SD): 4 ± 1.1; time to IV: 1.8 (0.6–2.9)[a]	5.2 (4–7.2)[a]	4.6 (1–13)[a]	4.4 (1–9.3)[a]	4.6 (1.7–12.5)[b]	4.9 (0.8–30)[b]
Early neurologic improvement	11 (65%)	13 (65%)	6 (38%)	16 (35%)	18 (44%)	55 (45%)
Early neurologic deterioration	2 (8%)	1 (5%)	3 (19%)	15 (32%)	5 (12%)	19 (16%)
Symptomatic ICH	0	1 (5%)	2 (13%)	4 (9%)	4 (10%)	8 (7%)
Mortality	2 (8%)	3 (15%)	6 (38%)	24 (52%)	11 (30%), missing 4	29 (24%)
mRS 0–2 at 1–3 months	6 (25%)	6 (30%)	6 (38%)	17 (37%)	14 (34%)	44 (39%), excluding 11

[a] Median (range).
[b] Mean (range).

On-line Table 3: Compilation and patient selection for the current analysis

	Study A[11]	Study B[12]	Study C[13]	Study D[14]	Study E[15]	Study F[16–20]	Total
Initial compilation	24	20	16	46	41	123	270
Excluded from analysis	5[a]	0	0	0	0	11[b]	16
Included in analysis	19	20	16	46	41	112	254
Complete recanalization	9 (47%)	8 (40%)	5 (31%)	17 (37%)	15 (37%)	42 (38%)	96 (38%)
Futile recanalization	5 (56%)	5 (63%)	5 (100%)	9 (53%)	10 (67%)	13 (31%)	47 (49%)

[a] No visualized arterial occlusion.
[b] No visualized arterial occlusion ($n = 6$), lost to follow-up ($n = 3$), age <18 ($n = 1$), no documented time of symptom onset ($n = 1$).

On-line Table 4: Univariate analysis comparing patients with and without futile recanalization

	All[a]	Nonfutile Recanalization[a]	Futile Recanalization[a]	*P* Value
Sample size	96 (100%)	49 (51%)	47 (49%)	
Age (mean ± SD); years	65 ± 15	58 ± 15	73 ± 11	<.0001
<40	5 (5%)	5 (10%)	0	
40–49	11 (11%)	10 (20%)	1 (2%)	
50–69	33 (34%)	18 (37%)	15 (32%)	
70–79	30 (31%)	14 (29%)	16 (34%)	
≥80	17 (18%)	2 (4%)	15 (32%)	
Women	39 (41%)	19 (39%)	20 (43%)	.84
Study type				.061
Prospective	39 (41%)	15 (31%)	24 (51%)	
Retrospective	57 (59%)	39 (69%)	23 (49%)	
Initial NIHSS score; median (range)	16 (4–42)	14 (4–27)	19 (7–42)	<.0001
<10	17 (18%)	14 (29%)	3 (6%)	
10–19	51 (53%)	30 (61%)	21 (45%)	
≥20	29 (30%)	5 (10%)	24 (51%)	
Vessel involved				.45
ICA	17 (18%)	7 (14%)	10 (21%)	.43
MCA	61 (64%)	37 (76%)	25 (53%)	.032
BA	11 (11%)	2 (4%)	8 (17%)	.049
VA	6 (6%)	2 (4%)	4 (9%)	.43
PCA	1 (1%)	1 (2%)	0	
Circulation				.12
Anterior	84 (88%)	46 (94%)	39 (83%)	
Posterior	12 (13%)	3 (6%)	8 (17%)	
Initial occlusion severity (Qureshi grade)[b]				.65
Mild (grade 0–2)	35 (37%)	18 (39%)	17 (35%)	
Severe (grade 3–5)	60 (63%)	28 (61%)	32 (65%)	
Time to treatment; median (range); minutes	256 (60–780)	240 (60–540)	263 (60–780)	.38
≤3 hours	27 (28%)	15 (31%)	12 (26%)	
3–6 hours	53 (55%)	26 (53%)	27 (57%)	
>6 hours	16 (17%)	8 (16%)	8 (17%)	
Symptomatic hemorrhagic complication	5 (5%)	1 (2%)	4 (9%)	.2

[a] Values represent frequency and rate except if otherwise stated.
[b] Six patients did not have a Qureshi grade available. TIMI score was used for 5 of these 6 patients. One patient had missing information for both Qureshi and TIMI grading.